Truist lowered the firm’s price target on UnitedHealth (UNH) to $310 from $345 and keeps a Buy rating on the shares. The firm is adjusting its model after the company’s Q2 results and reinstated FY25 guidance, the analyst tells investors in a research note. Truist adds it it lowering its FY25 EPS view to $16.18 from $21.72 and its FY26 view to $17.20 from $24.78.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Meta, Microsoft upgraded: Wall Street’s top analyst calls
- Humana price target lowered to $272 from $288 at Piper Sandler
- UnitedHealth price target lowered to $275 from $308 at TD Cowen
- UnitedHealth downgraded to Underperform from Neutral at Baird
- Cautious Outlook for UnitedHealth Amid Margin Adjustments and Revised Earnings Estimates